国药控股(1099.HK)：医药零售领衔 药械分销结构优化

Core Viewpoint - The company reported a revenue of 575.2 billion yuan in 2025, a decrease of 1.6% year-on-year, and a net profit attributable to shareholders of 7.16 billion yuan, an increase of 1.5% year-on-year, aligning with Wind consensus expectations [1] Group 1: Revenue and Profit Performance - The company's revenue and profit growth showed marginal improvement compared to the first three quarters of 2025, primarily due to the resilience in the pharmaceutical and medical device distribution sectors [1] - The retail sector's revenue growth was driven by enhanced "integrated wholesale and retail" and "dual-brand" collaborative income growth [1] - The profit growth outpaced revenue growth due to cost reduction and efficiency improvements, with an overall expense ratio decreasing by 0.25 percentage points [1] Group 2: Pharmaceutical Distribution - The pharmaceutical distribution segment generated revenue of 435.4 billion yuan in 2025, down 2.02% year-on-year, with an operating profit margin of 2.73%, remaining stable compared to the previous year [2] - The segment is expected to stabilize in 2026 due to ongoing optimization of product categories and strengthening market share in collective procurement and national negotiations [2] - The company is enhancing direct sales to high-tier hospitals and retail terminals while adjusting the product mix towards high-demand and high-value clinical needs [2] Group 3: Medical Device Distribution - The medical device distribution segment reported revenue of 115.5 billion yuan in 2025, also down 2.02% year-on-year, primarily due to deepening collective procurement in medical devices [2] - The outlook for 2026 is positive, driven by improved account management and a focus on high-value business segments [2] - The company is expanding its SPD (Supply, Processing, and Distribution) business, with a significant increase in project numbers and revenue growth [2] Group 4: Retail Business - The retail business achieved revenue of 38.4 billion yuan in 2025, an increase of 6.67% year-on-year, led by the professional pharmacy segment [3] - The operating profit margin for the retail segment improved to 1.56%, up 0.66 percentage points year-on-year, due to cost control measures [3] - The company anticipates continued revenue growth in 2026, supported by the strengthening of the professional pharmacy system and strategic store closures to enhance profitability [3] Group 5: Earnings Forecast and Valuation - The company projects EPS of 2.50, 2.71, and 2.89 yuan for 2026, 2027, and 2028 respectively, with a target price of 22.53 HKD based on an 8.2x PE ratio for 2026 [3]